Halder Venture Board Approves ₹50 Crore Capital Boost, ₹25 Crore Warrant Sale

Halder Venture Limited's board of directors has given the go-ahead for significant corporate actions, including a ₹50 crore increase in authorized share capital and the issuance of ₹25 crore in convertible warrants. These moves, approved on March 26, 2026, await shareholder consent via a postal ballot.

Raising Capital for Future Growth

The company plans to raise its authorized share capital from ₹134.25 crore to ₹184.25 crore. Alongside this, Halder Venture will issue 793,650 convertible warrants at ₹315 each to P.K. Bio Link Private Limited, aiming to raise approximately ₹25 crore. This capital infusion is expected to bolster the company's balance sheet and provide financial flexibility for future strategic initiatives.

New Auditor Appointed

In an operational update, the board appointed J Kumar Jain & Associates as the new Internal Auditor for the fiscal year 2025-26. They will succeed Somnath Ray & Associates.

Shareholder Approval and Dilution Risks

The success of both the capital increase and the warrant issuance depends on shareholder approval through an upcoming postal ballot. A primary risk for the company is failing to secure these votes, which would nullify the proposed actions. Existing shareholders should also be aware of potential equity dilution if the warrants are exercised.

What Investors Should Track

Investors will be watching for the outcome of the shareholder postal ballot closely. The company's announcements regarding meeting dates and voting results will be key. Additionally, any further details on the planned utilization of the potential capital infusion and developments with the new internal auditor will be important follow-up items.